World Stroke Congress 2026 - Abstract & Oral Presentation
Dimitri HemelsoetA, Robin LemmensB, Charlotte CorbisierC, Valérie PireauxC, Stéphanie DemoulinC, Sandrine DerochetteC, Cindy HespelC, Marie DagonnierD, Sofie De BlauweE, Adinda De PauwF, Sylvie De RaedtG, Philippe DesfontainesH, André PeetersI, Hans WarrinnierC
- A Department of Neurology, Gent University Hospital, Gent, Belgium
- B Department of Neurology, University Hospitals Leuven, Leuven, Belgium
- C Bioxodes, Gosselies, Belgium
- D Department of Neurology, CHU HELORA - Kennedy, Mons, Belgium
- E Department of Neurology, AZ Sint-Jan Brugge, Brugge, Belgium
- F Department of Neurology, AZ Oostende, Oostende, Belgium
- G Department of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Neuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium
- H Department of Neurology, Stroke Unit, CHC Groupe Santé, Liège, Belgium
- I Department of Neurology, Stroke Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Documents
Background and aim
Neuroinflammation driven by early neutrophil activation contributes to secondary brain injury after intracerebral hemorrhage (ICH). BIOX-101 is a novel investigational therapy with anti-neutrophil activity and inhibitory effect on coagulation factors XIa/XIIa. We evaluated the safety and efficacy of BIOX-101 added to standard of care (SoC) versus SoC alone in first-ever primary ICH.
Methods
In this randomized (3:1), open-label Phase IIa trial (NCT05970224), adults with supratentorial ICH (5-60 mL) were treated within 24 hours of onset with BIOX-101+SoC (n=17) or SoC alone (n=6). BIOX-101 was administered as a 48-hour infusion. Imaging endpoints were centrally adjudicated and blinded to treatment. PK/PD and neutrophil-to-lymphocyte ratio (NLR) were assessed up to 168 hours; safety and functional outcome (modified Rankin Scale [mRS]) up to Day 360. Analyses were descriptive.
Results
BIOX-101 achieved active plasma levels within <1 hour, with stable exposure and rapid, reversible pharmacodynamic effects (aPTT ratio ~2.5). Despite the randomized allocation of participants, the BIOX-101 cohort exhibited greater baseline hematoma and perihematomal edema volumes compared to SoC. However, data normalized to baseline volumes showed reduced hematoma expansion and perihematomal edema growth compared with SoC. Day 7 DW-MRI showed a low incidence of ischemic lesions or microhemorrhages. NLR remained low and stable in the BIOX-101 group but increased early under SoC, consistent with modulation of systemic inflammation. A favorable shift in mRS was observed in the BIOX-101 group.
Conclusions
BIOX-101 is safe, demonstrated rapid target engagement and showed encouraging signals of reduced secondary injury and improved recovery. These findings support advancement to a late-phase trial.